JP2012530705A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012530705A5 JP2012530705A5 JP2012516178A JP2012516178A JP2012530705A5 JP 2012530705 A5 JP2012530705 A5 JP 2012530705A5 JP 2012516178 A JP2012516178 A JP 2012516178A JP 2012516178 A JP2012516178 A JP 2012516178A JP 2012530705 A5 JP2012530705 A5 JP 2012530705A5
- Authority
- JP
- Japan
- Prior art keywords
- methyl
- pharmaceutically acceptable
- acceptable salt
- trifluoromethyl
- fluoro
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000003839 salts Chemical class 0.000 claims 10
- 239000011780 sodium chloride Substances 0.000 claims 10
- 150000001875 compounds Chemical class 0.000 claims 9
- 229910052739 hydrogen Inorganic materials 0.000 claims 7
- 239000001257 hydrogen Substances 0.000 claims 7
- UFHFLCQGNIYNRP-UHFFFAOYSA-N hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 4
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 4
- -1 trifluoromethoxy, difluoromethoxy, methylsulfonyl Chemical group 0.000 claims 4
- 150000002431 hydrogen Chemical class 0.000 claims 3
- 125000001309 chloro group Chemical group Cl* 0.000 claims 2
- 125000001153 fluoro group Chemical group F* 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 2
- 125000001889 triflyl group Chemical group FC(F)(F)S(*)(=O)=O 0.000 claims 2
- SZBGQDXLNMELTB-UHFFFAOYSA-N 4-fluoro-N-methyl-N-[1-[4-(2-methylpyrazol-3-yl)phthalazin-1-yl]piperidin-4-yl]-2-(trifluoromethyl)benzamide Chemical compound C=1C=C(F)C=C(C(F)(F)F)C=1C(=O)N(C)C(CC1)CCN1C(C1=CC=CC=C11)=NN=C1C1=CC=NN1C SZBGQDXLNMELTB-UHFFFAOYSA-N 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 125000004093 cyano group Chemical group *C#N 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 125000004216 fluoromethyl group Chemical group [H]C([H])(F)* 0.000 claims 1
- 150000003840 hydrochlorides Chemical class 0.000 claims 1
- 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 claims 1
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US21862809P | 2009-06-19 | 2009-06-19 | |
US61/218,628 | 2009-06-19 | ||
PCT/US2010/038568 WO2010147917A1 (en) | 2009-06-19 | 2010-06-15 | Disubstituted phthalazine hedgehog pathway antagonists |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2012530705A JP2012530705A (ja) | 2012-12-06 |
JP2012530705A5 true JP2012530705A5 (US07846941-20101207-C00217.png) | 2014-07-17 |
JP5596139B2 JP5596139B2 (ja) | 2014-09-24 |
Family
ID=42332981
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2012516178A Active JP5596139B2 (ja) | 2009-06-19 | 2010-06-15 | 二置換フタラジンヘッジホッグ経路アンタゴニスト |
Country Status (36)
Families Citing this family (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NZ588001A (en) * | 2008-04-29 | 2012-06-29 | Lilly Co Eli | Disubstituted phthalazine hedgehog pathway antagonists |
DK2364185T3 (da) * | 2008-11-03 | 2013-06-03 | Lilly Co Eli | Disubstituerede phthalazin-hedgehog-pathway-antagonister |
PL2358698T3 (pl) | 2008-11-17 | 2013-01-31 | Lilly Co Eli | Czteropodstawione pirydazyny jako antagoniści szlaku HEDGEHOG |
CN102216292B (zh) * | 2008-11-17 | 2014-08-13 | 伊莱利利公司 | 四取代的哒嗪hedgehog途径拮抗剂 |
AR077014A1 (es) | 2009-06-19 | 2011-07-27 | Lilly Co Eli | Compuesto derivado de ftalazina 1,4-disustituida, composicion farmaceutica que lo comprende y uso para preparar un medicamento util para el tratamiento de cancer |
WO2012127441A1 (en) | 2011-03-23 | 2012-09-27 | Semorex Technologies Ltd. | Treatment of proliferative disorders with a chemiluminescent agent |
GB201309508D0 (en) * | 2013-05-28 | 2013-07-10 | Redx Pharma Ltd | Compounds |
GB201311953D0 (en) * | 2013-07-03 | 2013-08-14 | Redx Pharma Ltd | Compounds |
WO2015073691A1 (en) | 2013-11-14 | 2015-05-21 | The Board Of Trustees Of The Leland Stanford Junior University | Methods for treating cancer by activation of bmp signaling |
CN105017140B (zh) * | 2014-04-28 | 2017-12-29 | 复旦大学 | 邻氨基苯甲酰胺化合物及其制备方法和用途 |
GB2528298A (en) * | 2014-07-16 | 2016-01-20 | Redx Pharma Plc | Compounds |
CN105985319B (zh) * | 2015-02-11 | 2019-02-26 | 复旦大学 | 芳基酞嗪化合物及其制备方法和用途 |
CN105985320B (zh) * | 2015-02-11 | 2018-10-26 | 复旦大学 | 苄基酞嗪化合物及其制备方法和用途 |
CN105985321B (zh) * | 2015-02-11 | 2018-10-26 | 复旦大学 | 吡唑酞嗪化合物及其制备方法和用途 |
JP6796638B2 (ja) | 2015-06-04 | 2020-12-09 | ペレファーム, インク.Pellepharm, Inc. | ヘッジホッグ阻害性化合物の送達のための局所的製剤及びその使用 |
WO2016196879A1 (en) * | 2015-06-05 | 2016-12-08 | Dana-Farber Cancer Institute, Inc. | Compounds and methods for treating cancer |
CA3017411A1 (en) | 2016-03-15 | 2017-09-21 | Oryzon Genomics, S.A. | Combinations of lsd1 inhibitors for use in the treatment of solid tumors |
CN106279114B (zh) * | 2016-08-04 | 2019-01-29 | 东南大学 | 一种Taladegib的合成方法 |
US10548908B2 (en) * | 2016-09-15 | 2020-02-04 | Nostopharma, LLC | Compositions and methods for preventing and treating heterotopic ossification and pathologic calcification |
CN106831718B (zh) * | 2016-12-30 | 2019-05-07 | 上海科技大学 | 平滑受体配体及其应用 |
EP3624798A1 (en) | 2017-05-18 | 2020-03-25 | Institut National de la Sante et de la Recherche Medicale (INSERM) | Methods and pharmaceutical compositions for the treatment of mast cell diseases |
KR20230031285A (ko) | 2020-06-26 | 2023-03-07 | 라퀄리아 파마 인코포레이티드 | 레티노이드와 암 치료제의 병용 요법이 효과적인 암 환자를 선별하는 방법 및 레티노이드와 암 치료제의 병용 의약 |
AU2021360767A1 (en) * | 2020-10-13 | 2023-04-27 | Endeavor Biomedicines, Inc. | Methods of treating fibrosis |
Family Cites Families (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IN148482B (US07846941-20101207-C00217.png) * | 1977-06-03 | 1981-03-07 | Pfizer | |
EP0876366B1 (en) | 1996-01-15 | 2001-07-25 | Janssen Pharmaceutica N.V. | Angiogenesis inhibiting pyridazinamines |
EP1067939B1 (en) | 1998-04-09 | 2015-09-16 | The Johns Hopkins University | Use of steroidal alkaloid derivatives as inhibitors of hedgehog protein signaling pathways |
DE60016402T2 (de) | 1999-06-08 | 2005-10-27 | Lorantis Ltd. | Therapeutische verwendung eines inhibitors des hedgehog signalübertragungsweges |
KR20040031782A (ko) * | 2001-07-27 | 2004-04-13 | 쿠리스 인코퍼레이션 | 헤지호그 신호전달 경로의 조절물질, 이를 함유하는조성물 및 이의 용도 |
CA2483311A1 (en) * | 2002-04-22 | 2003-10-30 | Philip A. Beachy | Modulators of hedgehog signaling pathways, compositions and uses related thereto |
AU2003265853A1 (en) | 2002-08-29 | 2004-03-19 | Curis, Inc. | Hedgehog antagonists, methods and uses related thereto |
WO2005033288A2 (en) | 2003-09-29 | 2005-04-14 | The Johns Hopkins University | Hedgehog pathway antagonists |
WO2005080378A1 (ja) | 2004-02-24 | 2005-09-01 | Mitsubishi Pharma Corporation | 縮合ピリダジン誘導体 |
AU2005260102A1 (en) | 2004-05-08 | 2006-01-12 | Novartis International Pharmaceutical Ltd. | 3-aryl-5,6-disubstituted pyridazines |
PL1789390T3 (pl) | 2004-09-02 | 2012-04-30 | Genentech Inc | Pirydylowe inhibitory szlaku sygnałowego hedgehog |
EP1900731A1 (de) * | 2006-09-07 | 2008-03-19 | Bayer Schering Pharma Aktiengesellschaft | N-(1-Phthalazin-1-yl-piperidin-4-yl)-amide als EP2-Rezeptor Modulatoren |
UA100684C2 (uk) | 2007-03-15 | 2013-01-25 | Новартіс Аг | Похідні бензилу та піридинілу як модулятори сигнального шляху hedgehog |
US8153633B2 (en) * | 2007-06-25 | 2012-04-10 | Amgen Inc. | Phthalazine compounds, compositions and methods of use |
WO2009035568A1 (en) | 2007-09-07 | 2009-03-19 | Amgen Inc. | Annelated pyridazines for the treatment of tumors driven by inappropriate hedgehog signalling |
US8592463B2 (en) * | 2007-12-13 | 2013-11-26 | Siena Biotech S.P.A. | Hedgehog pathway antagonists and therapeutic applications thereof |
NZ588001A (en) * | 2008-04-29 | 2012-06-29 | Lilly Co Eli | Disubstituted phthalazine hedgehog pathway antagonists |
US20100041663A1 (en) | 2008-07-18 | 2010-02-18 | Novartis Ag | Organic Compounds as Smo Inhibitors |
WO2010017240A2 (en) * | 2008-08-04 | 2010-02-11 | Amgen Inc. | Aurora kinase modulators and methods of use |
DK2364185T3 (da) | 2008-11-03 | 2013-06-03 | Lilly Co Eli | Disubstituerede phthalazin-hedgehog-pathway-antagonister |
CN102216292B (zh) | 2008-11-17 | 2014-08-13 | 伊莱利利公司 | 四取代的哒嗪hedgehog途径拮抗剂 |
PL2358698T3 (pl) | 2008-11-17 | 2013-01-31 | Lilly Co Eli | Czteropodstawione pirydazyny jako antagoniści szlaku HEDGEHOG |
AR077014A1 (es) | 2009-06-19 | 2011-07-27 | Lilly Co Eli | Compuesto derivado de ftalazina 1,4-disustituida, composicion farmaceutica que lo comprende y uso para preparar un medicamento util para el tratamiento de cancer |
-
2010
- 2010-06-08 AR ARP100102003A patent/AR077014A1/es active IP Right Grant
- 2010-06-10 JO JO2010188A patent/JO2931B1/en active
- 2010-06-11 TW TW099119158A patent/TWI385165B/zh not_active IP Right Cessation
- 2010-06-15 WO PCT/US2010/038568 patent/WO2010147917A1/en active Application Filing
- 2010-06-15 JP JP2012516178A patent/JP5596139B2/ja active Active
- 2010-06-15 EA EA201270049A patent/EA019059B1/ru not_active IP Right Cessation
- 2010-06-15 AU AU2010260244A patent/AU2010260244B2/en not_active Ceased
- 2010-06-15 SI SI201030200T patent/SI2443104T1/sl unknown
- 2010-06-15 UA UAA201114996A patent/UA106755C2/uk unknown
- 2010-06-15 NZ NZ596882A patent/NZ596882A/xx not_active IP Right Cessation
- 2010-06-15 CA CA2764542A patent/CA2764542C/en not_active Expired - Fee Related
- 2010-06-15 KR KR1020117030157A patent/KR101389165B1/ko active IP Right Grant
- 2010-06-15 DK DK10726756.9T patent/DK2443104T3/da active
- 2010-06-15 PL PL10726756T patent/PL2443104T3/pl unknown
- 2010-06-15 MX MX2011014029A patent/MX2011014029A/es active IP Right Grant
- 2010-06-15 SG SG2011094190A patent/SG177289A1/en unknown
- 2010-06-15 US US12/815,439 patent/US8273742B2/en active Active
- 2010-06-15 ES ES10726756T patent/ES2409054T3/es active Active
- 2010-06-15 CN CN201080027189.3A patent/CN102459233B/zh active Active
- 2010-06-15 PT PT107267569T patent/PT2443104E/pt unknown
- 2010-06-15 MA MA34455A patent/MA33363B1/fr unknown
- 2010-06-15 PE PE2011002119A patent/PE20121050A1/es active IP Right Grant
- 2010-06-15 MY MYPI2011006137A patent/MY156667A/en unknown
- 2010-06-15 BR BRPI1011601A patent/BRPI1011601A2/pt not_active Application Discontinuation
- 2010-06-15 EP EP10726756.9A patent/EP2443104B1/en active Active
-
2011
- 2011-11-22 ZA ZA2011/08587A patent/ZA201108587B/en unknown
- 2011-11-24 IL IL216599A patent/IL216599A/en not_active IP Right Cessation
- 2011-11-29 HN HN2011003139A patent/HN2011003139A/es unknown
- 2011-12-07 TN TNP2011000627A patent/TN2011000627A1/en unknown
- 2011-12-08 CR CR20110658A patent/CR20110658A/es unknown
- 2011-12-13 DO DO2011000386A patent/DOP2011000386A/es unknown
- 2011-12-14 CL CL2011003147A patent/CL2011003147A1/es unknown
- 2011-12-16 EC EC2011011541A patent/ECSP11011541A/es unknown
- 2011-12-22 CO CO11177210A patent/CO6480932A2/es not_active Application Discontinuation
-
2012
- 2012-06-11 HK HK12105676.6A patent/HK1164872A1/xx not_active IP Right Cessation
- 2012-08-21 US US13/590,481 patent/US9000023B2/en active Active
-
2013
- 2013-05-08 HR HRP20130408AT patent/HRP20130408T1/hr unknown